Prolia denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for prolia are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Prolia Under Quantity Limits

Prolia (denosumab) is administered on a fixed dosing schedule established in its FDA-approved prescribing label. UHC encodes this schedule into a quantity-limit edit in its claims system. A quantity-limit denial fires when a claim or request exceeds the units or frequency that UHC's system expects — for example, if an administration was billed sooner than the interval UHC's policy anticipates, or if the quantity submitted on a prescription differs from the formulary default.

Common real-world triggers include scheduling shifts (holiday rescheduling, urgent clinic visits), documentation gaps in the chart, or a clerical mismatch between the administered dose and the billed units. Because the FDA label itself establishes the appropriate dosing schedule, the appeal often succeeds when you show the administration was consistent with the label and clinically appropriate.

## Your Federal Appeal Rights

Under ACA §2719 and ERISA §503:

• You have the right to a full written explanation of which quantity limit was applied and why your claim exceeded it.
• If your physician documents that deviation from the standard interval was medically necessary (e.g., to prevent a lapse in bone-protective effect), that constitutes a medical exception and is separately appealable.
• External review is available after internal denial; the window is typically around four months — confirm the exact deadline in your denial letter.
• Expedited review is available when delay creates a meaningful health risk.

## The Appeal Process

1. Request the specific quantity-limit rule UHC applied, including the permitted units per period. 2. Pull the FDA prescribing label for Prolia and confirm your prescribed schedule is within labeled parameters. 3. If the administration was rescheduled or the timing deviated from the formulary default, obtain a prescriber note documenting the clinical reason. 4. Submit the appeal with the prescriber letter, the label excerpt, and any scheduling documentation explaining the discrepancy. 5. If the limit itself is more restrictive than the FDA label allows for your diagnosis, argue that the limit is not clinically grounded and request a medical exception.

## Documentation to Gather

• Administration records: Dates and times of each Prolia injection from the prescriber's and pharmacy's records.
• FDA label dosing section: Shows the approved interval — obtain from fda.gov or DailyMed.
• Prescriber explanation: If timing varied, a brief clinical note explaining why (e.g., patient illness, scheduling constraints, clinical urgency).
• Diagnosis and severity documentation: Chart notes confirming the ongoing need for continued therapy.
• UHC quantity-limit policy: Printed from uhcprovider.com; compare side-by-side with the FDA label.

## Criteria-Mapping Structure

Create a simple table: left column = UHC's stated quantity limit; right column = actual administration dates and units. Where they differ, explain the clinical reason in the adjacent cell. Attach the FDA label page. This format shows the reviewer exactly what happened and why it was appropriate, rather than asking them to reconstruct it from narrative alone.